1. +
U.S. Census Bureau Population Estimates by Demographic Characteristics. Table 2: Annual Estimates of the Population by Selected Age Groups and Sex for the United States: April 1, 2000 to July 1, 2004 (NC-EST2004-02) Population Division. US Census Bureau: June 9, 2005; 2013.
2. +
Vilazodone (Viibryd)—a new antidepressant.
Med Lett Drugs Ther. 2011;53:53–54.
3. +
Abo-Zena
RA, Bobek
MB, Dweik
RA: Hypertensive urgency induced by an interaction of
mirtazapine and
clonidine.
Pharmacotherapy. 2000;20:476–478.
4. +
Aframian
DJ: Oral adverse effects for
escitalopram (Cipralex).
Br J Dermatol. 2007;156:1046–1047.
5. +
Alberg
AJ, Carpenter
MJ: Enhancing the effectiveness of smoking cessation interventions: a cancer prevention imperative. J Natl Cancer Inst. 2012;104:260–262.
6. +
Amann
B, Hummel
B, Rall-Autenrieth
H
et al.: Bupropion-induced isolated impairment of sensory trigeminal nerve function. Int Clin Psychopharmacol. 2000;15:115–116.
7. +
Anonymous: Extrapyramidal effects of SSRI antidepressants. Prescrire Int. 2001;10:118–119.
8. +
Arias
HR, Santamaria
A, Ali
SF: Pharmacological and neurotoxicological actions mediated by
bupropion and
diethylpropion.
Int Rev Neurobiol. 2009;88:223–255.
9. +
Arinzon
ZH, Lehman
YA, Fidelman
ZG, Krasnyansky
II: Delayed recurrent SIADH associated with SSRIs. Ann Pharmacother. 2002;36:1175–1177.
10. +
Asnis
GM, Wetzler
S, Sanderson
WC
et al.: Functional interrelationship of serotonin and
norepinephrine: cortisol response to MCPP and DMI in patients with panic disorder, patients with depression, and normal control subjects.
Psychiatry Res. 1992;43:65–76.
11. +
Atkinson
JH, Slater
MA, Capparelli
EV
et al.: Efficacy of noradrenergic and serotonergic antidepressants in chronic back pain: a preliminary concentration-controlled trial. J Clin Psychopharmacol. 2007;27:135–142.
12. +
Bakheit
AM, Behan
PO, Prach
AT
et al.: A syndrome identical to the neuroleptic malignant syndrome induced by LSD and
alcohol.
Br J Addict. 1990;85:150–151.
13. +
Baldessarini
RJ Drugs and the treatment of psychiatric disorders. In: Hardman
JG, Limbird
LE, Molinoff
PB eds: Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 9th ed. New York: McGraw-Hill, 1996:431–459.
14. +
Baldwin
DS, Montgomery
SA, Nil
R, Lader
M: Discontinuation symptoms in depression and anxiety disorders. Neuropsychopharmacol. 2007;10:73–84.
15. +
Balit
CR, Lynch
CN, Isbister
GK:
Bupropion poisoning: a case series.
Med J Aust. 2003;178:61–63.
16. +
Banasr
M, Dwyer
JM, Duman
RS: Cell atrophy and loss in depression: reversal by antidepressant treatment. Curr Opin Cell Biol. 2011;23:730–737.
17. +
Banham
ND: Fatal
venlafaxine overdose.
Med J Aust. 1998;169:445.
18. +
Belson
MG, Kelley
TR:
Bupropion exposures: clinical manifestations and medical outcome.
J Emerg Med. 2002;23:223–230.
19. +
Benazzi
F:
Mirtazapine withdrawal symptoms.
Can J Psychiatry. 1998;43:525.
20. +
Beyenburg
S, Schonegger
K: Severe bradycardia in a stroke patient caused by a single low dose of
escitalopram.
Eur Neurol. 2007;57:50–51.
21. +
Bismuth-Evenzal
Y, Gonopolsky
Y, Gurwitz
D
et al.; Decreased serotonin content and reduced agonist-induced aggregation in platelets of patients chronically medicated with SSRI drugs. J Affect Disord. 2012;136:99–103.
22. +
Bissram
M, Scott
FD, Liu
L, Rosner
MH: Risk factors for symptomatic hyponatraemia: the role of pre-existing asymptomatic hyponatraemia. Intern Med J. 2007;37:149–155.
23. +
Black
K, Shea
C, Dursun
S, Kutcher
S: Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria. J Psychiatry Neurosci. 2000;25:255–261.
24. +
Blythe
D, Hackett
LP: Cardiovascular and neurological toxicity of
venlafaxine.
Hum Exp Toxicol. 1999;18:309–313.
25. +
Boeck
V, Overo
KF, Svendsen
O: Studies on acute toxicity and drug levels of
citalopram in the dog.
Acta Pharmacol Toxicol. 1982;50:169–174.
26. +
Borys
DJ, Setzer
SC, Ling
LJ
et al.: Acute
fluoxetine overdose: a report of 234 cases.
Am J Emerg Med. 1992;10:115–120.
27. +
Boyer
EW, Shannon
M: The serotonin syndrome. N Engl J Med. 2005;352:1112–1120.
28. +
Braitberg
G, Curry
SC: Seizure after isolated
fluoxetine overdose.
Ann Emerg Med. 1995;26:234–237.
29. +
Brauer
HR, Nowicki
PW, Catalano
G, Catalano
MC: Panic attacks associated with
citalopram.
South Med J. 2002;95:1088–1089.
30. +
Bremner
JD, Wingard
P, Walshe
TA: Safety of
mirtazapine in overdose.
J Clin Psychiatry. 1998;59:233–235.
31. +
Briley
M, Moret
C: Neurobiological mechanisms involved in antidepressant therapies. Clin Neuropharmacol. 1993;16:387–400.
32. +
Burgh
VDM
Citalopram Product Monograph. Copenhagen, Denmark: 1994.
33. +
Callaway
JC, Grob
CS: Ayahuasca preparations and serotonin reuptake inhibitors: a potential combination for severe adverse interactions. J Psychoactive Drugs. 1998;30:367–369.
34. +
Carvajal
A, Ortega
S, Del Olmo
L
et al.: Selective serotonin reuptake inhibitors and gastrointestinal bleeding: a case-control study. PLoS One. 2011;6:e19819.
35. +
Catalano
G, Catalano
MC, Epstein
MA, Tsambiras
PE: QTc interval prolongation associated with
citalopram overdose: a case report and literature review.
Clin Neuropharmacol. 2001;24:158–162.
36. +
Cochran
KA, Cavallari
LH, Shapiro
NL, Bishop
JR: Bleeding incidence with concomitant use of antidepressants and
warfarin.
Ther Drug Monit. 2011;33:433–438.
37. +
Cohen
RM, Pickar
D, Murphy
DL: Myoclonus-associated hypomania during MAO-inhibitor treatment. Am J Psychiatry. 1980;137:105–106.
38. +
Compton
R, Spiller
HA, Bosse
GM: Fatal
fluoxetine ingestion with postmortem blood concentrations.
Clin Toxicol. 2005;43:277–279.
39. +
Cox
NH, Gordon
PM, Dodd
H: Generalized pustular and erythrodermic psoriasis associated with
bupropion treatment.
Br J Dermatol. 2002;146:1061–1063.
40. +
Daniels
RJ: Serotonin syndrome due to
venlafaxine overdose.
J Accid Emerg Med. 1998;15:333–334.
41. +
Darmani
NA, Zhao
W: Production of serotonin syndrome by 8-OH DPAT in Cryptotis parva. Physiol Behav. 1998;65:327–331.
42. +
David
D, Esquenazi
J: Rhabdomyolysis associated with
bupropion treatment.
J Clin Psychopharmacol. 1999;19:185–186.
43. +
Davidson
J: Seizures and
bupropion: a review.
J Clin Psychiatry. 1989;50:256–261.
44. +
de Boer
T: The pharmacologic profile of
mirtazapine.
J Clin Psychiatry. 1996;57:19–25.
45. +
de Graaf
L, Diemont
WL: Chest pain during use of
bupropion as an aid in smoking cessation.
Br J Clin Pharmacol. 2003;56:451–452.
46. +
De Las Cuevas
C, Sanz
EJ: Duloxetine-induced excessive disturbing and disabling yawning. J Clin Psychopharmacol. 2007;27:106–107.
47. +
Delgado
PL: Monoamine depletion studies: implications for antidepressant discontinuation syndrome. J Clin Psychiatry. 2006;67:22–26.
48. +
Dent
LA, Brown
WC, Murney
JD: Citalopram-induced priapism. Pharmacotherapy. 2002;22:538–541.
49. +
Derby
MA, Zhang
L, Chappell
JC
et al.: The effects of supratherapeutic doses of
duloxetine on blood pressure and pulse rate.
J Cardiovasc Pharmacol. 2007;49:384–393.
50. +
Detweiler
MB, Harpold
GJ: Bupropion-induced acute dystonia. Ann Pharmacother. 2002;36:251–254.
51. +
Dugan
SE, Fuller
MA:
Duloxetine: a dual reuptake inhibitor.
Ann Pharmacother. 2004;38:2078–2085.
52. +
Dunkley
EJ, Isbister
GK, Sibbritt
D
et al.: The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96:635–642.
53. +
Evans
RW, Tepper
SJ, Shapiro
RE
et al.: The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper. Headache. 2010;50:1089–1099.
54. +
Ezzo
DC, Patel
PN: Facial flushing associated with
duloxetine use.
Am J Health Syst Pharm. 2007;64:495–496.
55. +
Fava
GA, Grandi
S: Withdrawal syndromes after
paroxetine and
sertraline discontinuation.
J Clin Psychopharmacol. 1995;15:374–375.
56. +
Fernandes
C, Reddy
P, Kessel
B: Rasagiline-induced serotonin syndrome. Mov Disord. 2011;26:766–767.
57. +
Francino
MC, Bretaudeau Deguigne
M, Badin
J
et al.: Hypoglycaemia: a little known effect of
Venlafaxine overdose.
Clin Toxicol. 2012;50:215–217.
58. +
Friberg
LE, Isbister
GK, Duffull
SB: Pharmacokinetic-pharmacodynamic modelling of QT interval prolongation following
citalopram overdoses.
Br J Clin Pharmacol. 2006;61:177–190.
59. +
Friberg
LE, Isbister
GK, Hackett
LP, Duffull
SB: The population pharmacokinetics of
citalopram after deliberate self-poisoning: a Bayesian approach.
J Pharmacokinet Pharmacodyn. 2005;32:571–605.
60. +
Friel
PN, Logan
BK, Fligner
CL: Three fatal drug overdoses involving
bupropion. J
Anal Toxicol. 1993;17:436–438.
61. +
Fuller
RW: Serotonergic stimulation of pituitary-adrenocortical function in rats. Neuroendocrinology. 1981;32:118–127.
62. +
Gamble
DE, Peterson
LG:
Trazodone overdose: four years of experience from voluntary reports.
J Clin Psychiatry. 1986;47:544–546.
63. +
Gartlehner
G, Hansen
RA, Morgan
LC
et al.: Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis. Ann Intern Med. 2011;155:772–785.
64. +
Gerson
SC, Baldessarini
RJ: Motor effects of serotonin in the central nervous system. Life Sci. 1980;27:1435–1451.
65. +
Gillman
PK: The serotonin syndrome and its treatment. J Psychopharmacol. 1999;13:100–109.
66. +
Gillman
PK: Possible serotonin syndrome with
moclobemide and pethidine.
Med J Aust. 1995;162:554.
67. +
Givens
ML, Gabrysch
J: Cardiotoxicity associated with accidental
bupropion ingestion in a child.
Pediatr Emerg Care. 2007;23:234–237.
68. +
Goeringer
KE, Raymon
L, Christian
GD, Logan
BK: Postmortem forensic toxicology of selective serotonin reuptake inhibitors: a review of pharmacology and report of 168 cases. J Forensic Sci. 2000;45:633–648.
69. +
Goldberg
RJ, Huk
M: Serotonin syndrome from
trazodone and
buspirone.
Psychosomatics. 1992;33:235–236.
70. +
Goren
JL, Levin
GM: Mania with
bupropion: a dose-related phenomenon?
Ann Pharmacother. 2000;34:619–621.
71. +
Graber
MA, Hoehns
TB, Perry
PJ: Sertraline-phenelzine drug interaction: a serotonin syndrome reaction. Ann Pharmacother. 1994;28:732–735.
72. +
Graudins
A, Stearman
A, Chan
B: Treatment of the serotonin syndrome with
cyproheptadine.
J Emerg Med. 1998;16:615–619.
73. +
Greenblatt
DJ, von Moltke
LL, Harmatz
JS, Shader
RI: Human cytochromes and some newer antidepressants: kinetics, metabolism, and drug interactions. J Clin Psychopharmacol. 1999;19:23S–35S.
74. +
Grundemar
L, Wohlfart
B, Lagerstedt
C
et al.: Symptoms and signs of severe
citalopram overdose.
Lancet. 1997;349:1602.
75. +
Guze
BH, Baxter
LR
Jr The serotonin syndrome: case responsive to
propranolol.
J Clin Psychopharmacol. 1986;6:119–120.
76. +
Haddad
P: Newer antidepressants and the discontinuation syndrome. J Clin Psychiatry. 1997;58:17–21.
77. +
Hanekamp
BB, Zijlstra
JG, Tulleken
JE
et al.: Serotonin syndrome and rhabdomyolysis in
venlafaxine poisoning: a case report.
Neth J Med. 2005;63:316–318.
78. +
Harmon
T, Jurta
D, Krenzelok
E: Delayed seizures from sustained-release
bupropion overdose.
Clin Toxicol. 1998;36:522.
79. +
Harris
CR, Gualtieri
J, Stark
G: Fatal
bupropion overdose.
Clin Toxicol. 1997;35:321–324.
80. +
Hawton
K, Bergen
H, Simkin
S
et al.: Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose. Br J Psychiatry. 2010;196:354–358.
81. +
Hernandez
JL, Ramos
FJ, Infante
J
et al.: Severe serotonin syndrome induced by
mirtazapine monotherapy.
Ann Pharmacother. 2002;36:641–643.
82. +
Himei
A, Okamura
T: Discontinuation syndrome associated with
paroxetine in depressed patients: a retrospective analysis of factors involved in the occurrence of the syndrome.
CNS Drugs. 2006;20:665–672.
83. +
Hoes
MJ, Zeijpveld
JH:
Mirtazapine as treatment for serotonin syndrome.
Pharmacopsychiatry. 1996;29:81.
84. +
Horak
EL, Jenkins
AJ: Postmortem tissue distribution of
olanzapine and
citalopram in a drug intoxication.
J Forensic Sci. 2005;50:679–681.
85. +
Hui
CK, Yuen
MF, Wong
WM
et al.: Mirtazapine-induced hepatotoxicity. J Clin Gastroenterol. 2002;35:270–271.
86. +
Isbister
GK, Friberg
LE, Stokes
B
et al.: Activated charcoal decreases the risk of QT prolongation after
citalopram overdose.
Ann Emerg Med. 2007;50:593–600.
87. +
Jewell
DP, Thompson
IW, Sullivan
BA, Bondeson
J: Reversible focal myositis in a patient taking
venlafaxine.
Rheumatology. 2004;43:1590–1593.
88. +
Johnsen
CR, Hoejlyng
N: Hyponatremia following acute overdose with
paroxetine.
Int J Clin Pharmacol Ther. 1998;36:333–335.
89. +
Johnston
JA, Lineberry
CG, Ascher
JA
et al.: A 102-center prospective study of seizure in association with
bupropion.
J Clin Psychiatry. 1991;52:450–456.
90. +
Kato
M, Okugawa
G, Wakeno
M
et al.: Effect of basic fibroblast growth factor (FGF2) gene polymorphisms on SSRIs treatment response and side effects. Eur Neuropsychopharmacol. 2009;19:718–725.
91. +
Kato
M, Fukuda
T, Wakeno
M
et al.: Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder. Am J Med Genet B Neuropsychiatr Genet. 2009;150B:115–123.
92. +
Keltner
NL, Hall
S: Neonatal serotonin syndrome. Perspect Psychiatr Care. 2005;41:88–91.
93. +
Kessler
RC, Chiu
WT, Demler
O
et al.: Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication.
Arch Gen Psychiatry.[Archives of General Psychiatry Full Text] 2005;62:617–627.
94. +
Kessler
RC, Berglund
P, Demler
O
et al.: Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.
Arch Gen Psychiatry.[Archives of General Psychiatry Full Text] 2005;62:593–602.
95. +
Kessler
RC, Berglund
P, Demler
O
et al.: The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).
JAMA.[JAMA and JAMA Network Journals Full Text] 2003;289:3095–3105.
96. +
Khoo
AL, Tham
LS, Lee
KH, Lim
GK: Acute liver failure with concurrent
bupropion and carbimazole therapy.
Ann Pharmacother. 2003;37:220–223.
97. +
Kincaid
RL, McMullin
MM, Crookham
SB, Rieders
F: Report of a
fluoxetine fatality.
J Anal Toxicol. 1990;14:327–329.
98. +
Kirchner
V,
Silver
LE, Kelly
CA: Selective serotonin reuptake inhibitors and hyponatraemia: review and proposed mechanisms in the elderly.
J Psychopharmacol. 1998;12:396–400.
99. +
Kitson
R, Carr
B:
Tramadol and severe serotonin syndrome.
Anaesthesia. 2005;60:934–935.
100. +
Krasowska
D, Szymanek
M, Schwartz
RA, Myliski
W: Cutaneous effects of the most commonly used antidepressant medication, the selective serotonin reuptake inhibitors. J Am Acad Dermatol. 2007;56:848–853.
101. +
Kruithof
MK, Bruins
NA, van Roon
EN: Coma after overdose with
duloxetine.
Ann Pharmacother. 2011;45:e5.
102. +
Kumar
VV, Isbister
GK, Duffull
SB: The effect of decontamination procedures on the pharmacodynamics of
venlafaxine in overdose.
Br J Clin Pharmacol. 2011;72:125–132.
103. +
Kumar
VV, Oscarsson
S, Friberg
LE
et al.: The effect of decontamination procedures on the pharmacokinetics of
venlafaxine in overdose.
Clin Pharmacol Ther. 2009;86:403–410.
104. +
Lane
RM: SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment. J Psychopharmacol. 1998;12:192–214.
105. +
Lappin
RI, Auchincloss
EL: Treatment of the serotonin syndrome with
cyproheptadine.
N Engl J Med. 1994;331:1021–1022.
106. +
Lejoyeux
M, Ades
J: Antidepressant discontinuation: a review of the literature. J Clin Psychiatry. 1997;58:11–15.
107. +
Lejoyeux
M, Rouillon
F, Ades
J: Prospective evaluation of the serotonin syndrome in depressed inpatients treated with
clomipramine.
Acta Psychiatr Scand. 1993;88:369–371.
108. +
Lenzer
J: Secret US report surfaces on antidepressants in children. BMJ. 2004;329:307.
109. +
Levine
M, Truitt
CA, O’Connor
AD: Cardiotoxicity and serotonin syndrome complicating a
milnacipran overdose.
J Med Toxicol. 2011;7:312–316.
110. +
Levinson
ML, Lipsy
RJ, Fuller
DK: Adverse effects and drug interactions associated with
fluoxetine therapy.
DICP. 1991;25:657–661.
111. +
Lineberry
TW, Peters
GE
Jr, Bostwick
JM: Bupropion-induced erythema multiforme. Mayo Clin Proc. 2001;76:664–666.
112. +
Liu
PT, Argento
V, Skudlarska
B, Blagodatny
M: Serotonin syndrome in an octogenarian after switch from
fluoxetine to
duloxetine.
J Am Geriatr Soc. 2009;57:2384.
113. +
LoVecchio
F, Riley
B, Pizon
A, Brown
M: Outcomes after isolated
mirtazapine (Remeron) supratherapeutic ingestions.
J Emerg Med. 2008;34:77–78.
114. +
Luchini
D, Morabito
G, Centini
F: Case report of a fatal intoxication by
citalopram.
Am J Forensic Med Pathol. 2005;26:352–354.
115. +
Makowski
CT, Gwinn
KM, Hurren
KM:
Naltrexone/
bupropion: an investigational combination for weight loss and maintenance.
Obes Facts. 2011;4:489–494.
116. +
Marar
IE, Towers
AL, Mulsant
BH
et al.: Effect of
paroxetine on plasma
vasopressin and water load testing in elderly individuals.
J Geriatr Psychiatry Neurol. 2000;13:212–216.
117. +
Masullo
LN, Miller
MA, Baker
SD
et al.: Clinical course and toxicokinetic data following isolated
citalopram overdose in an infant.
Clin Toxicol. 2006;44:165–168.
118. +
Maurer-Spurej
E: Serotonin reuptake inhibitors and cardiovascular diseases: a platelet connection. Cell Mol Life Sci. 2005;62:159–170.
119. +
Megarbane
B, Bloch
V, Deye
N, Baud
FJ: Pharmacokinetic/pharmacodynamic modelling of cardiac toxicity in
venlafaxine overdose.
Intensive Care Med. 2007;33:195–196.
120. +
Miller
F, Friedman
R, Tanenbaum
J, Griffin
A: Disseminated intravascular coagulation and acute myoglobinuric renal failure: a consequence of the serotonergic syndrome. J Clin Psychopharmacol. 1991;11:277–279.
121. +
Movig
KL, Leufkens
HG, Lenderink
AW, Egberts
AC: Serotonergic antidepressants associated with an increased risk for hyponatraemia in the elderly.
Eur J Clin Pharmacol. 2002;58:143–148.
122. +
Movig
KL, Leufkens
HG, Belitser
SV
et al.: Selective serotonin reuptake inhibitor-induced urinary incontinence. Pharmacoepidemiol Drug Saf. 2002;11:271–279.
123. +
Munhoz
RP: Serotonin syndrome induced by a combination of
bupropion and SSRIs.
Clin Neuropharmacol. 2004;27:219–222.
124. +
Murata
Y, Kobayashi
D, Imuta
N
et al.: Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of
paroxetine discontinuation syndrome.
J Clin Psychopharmacol. 2010;30:11–17.
125. +
Naranjo
CA, Bremner
KE: Clinical pharmacology of serotonin-altering medications for decreasing
alcohol consumption.
Alcohol Alcohol Suppl. 1993;2:221–229.
126. +
Nelson
JC: Safety and tolerability of the new antidepressants. J Clin Psychiatry. 1997;58:26–31.
127. +
Nelson
LS, Erdman
AR, Booze
LL
et al.: Selective serotonin reuptake inhibitor poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol. 2007;45:315–332.
128. +
Nisijima
K, Ishiguro
T: Cerebrospinal fluid levels of monoamine metabolites and gamma-aminobutyric acid in neuroleptic malignant syndrome. J Psychiatr Res. 1995;29:233–244.
129. +
Nutt
D:
Mirtazapine: pharmacology in relation to adverse effects.
Acta Psychiatr Scand. 1997;391:31–37.
130. +
Oates
JA, Sjoerdsma
A: Neurologic effects of
tryptophan in patients receiving a monoamine oxidase inhibitor.
Neurology. 1960;10:1076–1078.
131. +
O’Reardon
JP, Allison
KC, Martino
NS
et al.: A randomized, placebo-controlled trial of
sertraline in the treatment of night eating syndrome.
Am J Psychiatry. 2006;163:893–898.
132. +
Paris
PA, Saucier
JR: ECG conduction delays associated with massive
bupropion overdose.
Clin Toxicol. 1998;36:595–598.
133. +
Paruchuri
P, Godkar
D, Anandacoomarswamy
D
et al.: Rare case of serotonin syndrome with therapeutic doses of
paroxetine.
Am J Ther. 2006;13:550–552.
134. +
Pascale
P, Oddo
M, Pacher
P
et al.: Severe rhabdomyolysis following
venlafaxine overdose.
Ther Drug Monit. 2005;27:562–564.
135. +
Peacock
LE, Wright
F; Serotonin syndrome secondary to
tramadol and
citalopram.
Age Ageing. 2011;40:528.
136. +
Pereira
CE, Goldman-Levine
JD: Extended-release venlafaxine-induced alopecia. Ann Pharmacother. 2007;41:1084.
137. +
Pergola
PE, Sved
AF, Voogt
JL, Alper
RH: Effect of serotonin on
vasopressin release: a comparison to corticosterone, prolactin and renin.
Neuroendocrinology. 1993;57:550–558.
138. +
Personne
M, Persson
H, Sjoberg
E:
Citalopram toxicity.
Lancet. 1997;350:518–519.
139. +
Personne
M, Sjoberg
G, Persson
H:
Citalopram overdose—review of cases treated in Swedish hospitals.
Clin Toxicol. 1997;35:237–240.
140. +
Popli
AP, Tanquary
J, Lamparella
V, Masand
PS:
Bupropion and anticonvulsant drug interactions.
Ann Clin Psychiatry. 1995;7:99–101.
141. +
Price
JS, Waller
PC, Wood
SM, MacKay
AV: A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmacol. 1996;42:757–763.
142. +
Putzhammer
A, Schoeler
A, Rohrmeier
T
et al.: Evidence of a role for the 5-HTTLPR genotype in the modulation of motor response to antidepressant treatment. Psychopharmacology. 2005;178:303–308.
143. +
Rajamani
S, Eckhardt
LL, Valdivia
CR
et al.: Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by
fluoxetine and norfluoxetine.
Br J Pharmacol. 2006;149:481–489.
144. +
Retz
W, Maier
S, Maris
F, Rosler
M: Non-fatal
mirtazapine overdose.
Int Clin Psychopharmacol. 1998;13:277–279.
146. +
Richelson
E: Pharmacology of antidepressants. Mayo Clin Proc. 2001;76:511–527.
147. +
Richelson
E: Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. Mayo Clin Proc. 1997;72:835–847.
148. +
Rohrig
TP, Ray
NG: Tissue distribution of
bupropion in a fatal overdose.
J Anal Toxicol. 1992;16:343–345.
149. +
Rudolph
RL, Derivan
AT: The safety and tolerability of
venlafaxine hydrochloride: analysis of the clinical trials database.
J Clin Psychopharmacol. 1996;16:54S–59S.
150. +
Sandyk
R: L-dopa induced “serotonin syndrome” in a parkinsonian patient on
bromocriptine.
J Clin Psychopharmacol. 1986;6:194–195.
151. +
Sargent
PA, Kjaer
KH, Bench
CJ
et al.: Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment.
Arch Gen Psychiatry.[Archives of General Psychiatry Full Text] 2000;57:174–180.
152. +
Schatzberg
AF, Blier
P, Delgado
PL
et al.: Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. J Clin Psychiatry. 2006;67:27–30.
153. +
Schatzberg
AF, Haddad
P, Kaplan
EM
et al.: Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. Discontinuation Consensus panel. J Clin Psychiatry. 1997;58:5–10.
154. +
Schillevoort
I, van Puijenbroek
EP, de Boer
A
et al.: Extrapyramidal syndromes associated with selective serotonin reuptake inhibitors: a case-control study using spontaneous reports. Int Clin Psychopharmacol. 2002;17:75–79.
155. +
Schwartz
AR, Pizon
AF, Brooks
DE: Dextromethorphan-induced serotonin syndrome. Clin Toxicol. 2008;46:771–773.
156. +
Schweizer
E, Weise
C, Clary
C
et al.: Placebo-controlled trial of
venlafaxine for the treatment of major depression.
J Clin Psychopharmacol. 1991;11:233–236.
157. +
Service
JA, Waring
WS: QT Prolongation and delayed atrioventricular conduction caused by acute ingestion of
trazodone.
Clin Toxicol. 2008;46:71–73.
158. +
Shaw
MW, Sheard
JD: Fatal
venlafaxine overdose with acinar zone 3 liver cell necrosis.
Am J Forensic Med Pathol. 2005;26:367–368.
159. +
Sirianni
AJ, Osterhoudt
KC, Calello
DP
et al.: Use of lipid emulsion in the resuscitation of a patient with prolonged cardiovascular collapse after overdose of
bupropion and
lamotrigine.
Ann Emerg Med. 2008;51:412–415.
160. +
Sitsen
J, Maris
F, Timmer
C: Drug-drug interaction studies with
mirtazapine and
carbamazepine in healthy male subjects.
Eur J Drug Metab Pharmacokinet. 2001;26:109–121.
161. +
Smith
B, Prockop
DJ: Central-nervous-system effects of ingestin of l-tryptophan by normal subjects. N Engl J Med. 1962;267:1338–1341.
162. +
Snyder
SH, Peroutka
SJ: A possible role of serotonin receptors in antidepressant drug action. Pharmacopsychiatria. 1982;15:131–134.
163. +
Spaans
E, van den Heuvel
MW, Schnabel
PG
et al.: Concomitant use of
mirtazapine and
phenytoin: a drug-drug interaction study in healthy male subjects.
Eur J Clin Pharmacol. 2002;58:423–429.
164. +
Spigset
O, Hagg
S, Bate
A: Hepatic injury and pancreatitis during treatment with serotonin reuptake inhibitors: data from the World Health Organization (WHO) database of adverse drug reactions. Int Clin Psychopharmacol. 2003;18:157–161.
165. +
Sprouse
JS, Aghajanian
GK: (-)-Propranolol blocks the inhibition of serotonergic dorsal raphe cell firing by 5-HT1A selective agonists. Eur J Pharmacol. 1986;128:295–298.
166. +
Starr
P, Klein-Schwartz
W, Spiller
H
et al.: Incidence and onset of delayed seizures after overdoses of extended-release
bupropion.
Am J Emerg Med. 2009;27:911–915.
167. +
Stedman
CA, Begg
EJ, Kennedy
MA
et al.: Cytochrome P450 2D6 genotype does not predict SSRI (
fluoxetine or
paroxetine) induced hyponatraemia.
Hum Psychopharmacol. 2002;17:187–190.
168. +
Steele
D, Keltner
NL, McGuiness
TM: Are neuroleptic malignant syndrome and serotonin syndrome the same syndrome? Perspect Psychiatr Care. 2011;47:58–62.
169. +
Sternbach
H: The serotonin syndrome. Am J Psychiatry. 1991;148:705–713.
170. +
Tamam
L, Ozpoyraz
N: Selective serotonin reuptake inhibitor discontinuation syndrome: a review. Adv Ther. 2002;19:17–26.
171. +
Tarabar
AF, Hoffman
RS, Nelson
L:
Citalopram overdose: late presentation of torsades de pointes (TdP) with cardiac arrest.
J Med Toxicol. 2008;4:101–105.
172. +
Tripathi
A, Greenberger
PA:
Bupropion hydrochloride induced serum sickness-like reaction.
Ann Allergy Asthma Immunol. 1999;83:165–166.
173. +
Unterecker
S, Warrings
B, Deckert
J, Pfuhlmann
B: Correlation of QTc interval prolongation and serum level of
citalopram after intoxication—a case report.
Pharmacopsychiatry. 2012;45:30–34.
174. +
van Gorp
F, Duffull
S, Hackett
LP, Isbister
GK: Population pharmacokinetics and pharmacodynamics of
escitalopram in overdose and the effect of activated charcoal.
Br J Clin Pharmacol. 2012;73:402–410.
175. +
Vanpee
D, Laloyaux
P, Gillet
JB: Seizure and hyponatraemia after overdose of trazadone. Am J Emerg Med. 1999;17:430–431.
176. +
Vetulani
J, Stawarz
RJ, Dingell
JV, Sulser
F; A possible common mechanism of action of antidepressant treatments: reduction in the sensitivity of the noradrenergic cyclic AMP gererating system in the rat limbic forebrain. Naunyn-Schmiedeberg’s Arch Pharmacol. 1976;293:109–114.
177. +
von Moltke
LL, Greenblatt
DJ, Giancarlo
GM
et al.:
Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram.
Drug Metab Dispos. 2001;29:1102–1109.
178. +
Waring
WS, Good
AM, Bateman
DN: Lack of significant toxicity after
mirtazapine overdose: a five-year review of cases admitted to a regional toxicology unit.
Clin Toxicol. 2007;45:45–50.
179. +
Weller
EB, Weller
RA, Kloos
AL
et al.: Impact of depression and its treatment on the bones of growing children. Curr Psychiatry Rep. 2007;9:94–98.
180. +
White
CM, Gailey
RA, Levin
GM, Smith
T: Seizure resulting from a
venlafaxine overdose.
Ann Pharmacother. 1997;31:178–180.
181. +
Willner
P:
Dopamine and depression: a review of recent evidence. I. Empirical studies.
Brain Res. 1983;287:211–224.
182. +
Wong
DT, Bymaster
FP, Horng
JS, Molloy
BB: A new selective inhibitor for uptake of serotonin into synaptosomes of rat brain: 3-(p-trifluoromethylphenoxy). N-methyl-3-phenylpropylamine. J Pharmacol Exp Ther. 1975;193:804–811.
183. +
Woodrum
ST, Brown
CS: Management of SSRI-induced sexual dysfunction. Ann Pharmacother. 1998;32:1209–1215.
184. +
Yolles
JC, Armenta
WA, Alao
AO: Serum sickness induced by
bupropion.
Ann Pharmacother. 1999;33:931–933.
185. +
Yuksel
FV, Tuzer
V, Goka
E:
Escitalopram intoxication.
Eur Psychiatry. 2005;20:82.
186. +
Zhalkovsky
B, Walker
D, Bourgeois
JA: Seizure activity and enzyme elevations after
venlafaxine overdose.
J Clin Psychopharmacol. 1997;17:490–491.